Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
Technology appraisal guidance
Reference number: TA1054
Published:
The appraisal is expected to start during March 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-April 2024.